Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML
(MedPage Today) -- There was bad news and good news in a phase III trial evaluating intensive chemotherapy with or without gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia (AML) patients with newly diagnosed, NPM1-mutated disease.
For...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Hematology | Leukemia